HTG Molecular Diagnostics’ (HTGM) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of HTG Molecular Diagnostics (NASDAQ:HTGM) in a research note issued to investors on Tuesday morning, AnalystRatings.com reports. HC Wainwright currently has a $2.00 price objective on the medical research company’s stock.

Other equities research analysts have also issued research reports about the company. ValuEngine upgraded HTG Molecular Diagnostics from a sell rating to a hold rating in a research note on Tuesday, December 3rd. Cantor Fitzgerald reiterated an overweight rating on shares of HTG Molecular Diagnostics in a research note on Friday, October 18th. Craig Hallum set a $3.00 price objective on HTG Molecular Diagnostics and gave the company a buy rating in a research note on Friday, September 27th. Finally, Canaccord Genuity set a $1.50 price objective on HTG Molecular Diagnostics and gave the company a buy rating in a research note on Thursday, September 26th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. HTG Molecular Diagnostics has an average rating of Buy and an average target price of $3.13.

Shares of HTGM stock traded down $0.03 during trading hours on Tuesday, reaching $0.63. The company had a trading volume of 23,835 shares, compared to its average volume of 374,212. The company has a debt-to-equity ratio of 0.34, a quick ratio of 5.07 and a current ratio of 5.21. HTG Molecular Diagnostics has a twelve month low of $0.56 and a twelve month high of $3.24. The company has a market capitalization of $35.35 million, a P/E ratio of -1.09 and a beta of 1.56. The stock’s fifty day simple moving average is $0.70 and its 200 day simple moving average is $0.90.

HTG Molecular Diagnostics (NASDAQ:HTGM) last posted its earnings results on Tuesday, November 12th. The medical research company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. HTG Molecular Diagnostics had a negative return on equity of 88.60% and a negative net margin of 76.97%. The business had revenue of $5.41 million during the quarter, compared to analyst estimates of $5.63 million. As a group, equities analysts expect that HTG Molecular Diagnostics will post -0.56 earnings per share for the current year.

Several institutional investors and hedge funds have recently modified their holdings of HTGM. BlackRock Inc. grew its position in shares of HTG Molecular Diagnostics by 504.3% in the 2nd quarter. BlackRock Inc. now owns 405,837 shares of the medical research company’s stock worth $673,000 after acquiring an additional 338,681 shares in the last quarter. Vanguard Group Inc. raised its stake in HTG Molecular Diagnostics by 20.0% during the 2nd quarter. Vanguard Group Inc. now owns 1,453,160 shares of the medical research company’s stock valued at $2,413,000 after acquiring an additional 242,497 shares in the last quarter. Citadel Advisors LLC raised its stake in HTG Molecular Diagnostics by 153.9% during the 2nd quarter. Citadel Advisors LLC now owns 38,525 shares of the medical research company’s stock valued at $64,000 after acquiring an additional 23,351 shares in the last quarter. Finally, Perkins Capital Management Inc. raised its stake in HTG Molecular Diagnostics by 297.1% during the 3rd quarter. Perkins Capital Management Inc. now owns 2,353,153 shares of the medical research company’s stock valued at $1,564,000 after acquiring an additional 1,760,533 shares in the last quarter. Institutional investors own 38.94% of the company’s stock.

About HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing.

Recommended Story: Purposes and Functions of the Federal Reserve

Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.